[The future of antibody fragments, made of a single immunoglobulin domain].
Monoclonal antibodies are now established as key therapeutics for a range of diseases including cancer and auto-immunity. However, despite important improvements, these molecules still face several serious limitations including production costs and tumor penetration. A new class of antibody fragments, made of a single immunoglobulin domain, is emerging as an exciting alternative. This review describes the outstanding properties and the first achievements of these domain antibodies.Read the article